{"id":"indacaterol-glycopyrronium-110-50-breezhaler","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Indacaterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and lasting up to 24 hours. Glycopyrronium blocks muscarinic acetylcholine receptors, providing additional bronchodilation and reducing mucus production. The combination provides dual bronchodilation through complementary mechanisms for sustained airway opening.","oneSentence":"Indacaterol is a long-acting beta-2 agonist and glycopyrronium is an anticholinergic that together relax airway smooth muscle and reduce mucus secretion to improve airflow in chronic obstructive pulmonary disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:40.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT03379233","phase":"PHASE3","title":"A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":7},{"nctId":"NCT02576626","phase":"PHASE4","title":"Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD","status":"COMPLETED","sponsor":"Wouter H. van Geffen","startDate":"2015-12","conditions":"COPD","enrollment":40},{"nctId":"NCT01996319","phase":"PHASE3","title":"Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":194}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ultibro"],"phase":"marketed","status":"active","brandName":"indacaterol/glycopyrronium 110/50 Breezhaler®","genericName":"indacaterol/glycopyrronium 110/50 Breezhaler®","companyName":"Wouter H. van Geffen","companyId":"wouter-h-van-geffen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indacaterol is a long-acting beta-2 agonist and glycopyrronium is an anticholinergic that together relax airway smooth muscle and reduce mucus secretion to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}